Abstract
In humans, the zinc-dependent histone deacetylases (HDACs) are a family of 11 nonredundant isoforms that catalyze the dynamic reversal of posttranslationally modified acyl-lysine residues back to lysine. At the epigenetic level, HDACs have a critical gene silencing effect, promoting the compaction of histone tails with DNA to prevent transcription. In addition, HDACs deacylate many nonhistone substrates in diverse cellular compartments to profoundly influence protein structure and function. While the action of HDACs is indispensable to normal physiology, their abnormal overexpression is linked to the majority of human diseases. Consequently, the inhibition of HDACs has become a valuable target for therapeutic applications. Numerous potent small molecules are known, of both natural product and synthetic origin, that inhibit HDACs, primarily by reversibly interacting with the zinc cation within the enzyme active site. At the present time, five such HDAC inhibitors have received regulatory approval for the treatment of hematological cancers. This review focuses on the typical zinc-binding groups employed in HDAC inhibitors and the major advances within each class in terms of potency, isoform selectivity, and clinical applications.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- BCL2:
-
B-cell lymphoma 2
- CoREST:
-
Corepressor RE1 silencing transcription factor
- EGFR:
-
Epidermal growth factor receptor
- EMA:
-
European medicines agency
- FDA:
-
Food and drug administration
- HAT:
-
Histone acetyltransferase
- HDAC:
-
Histone deacetylase
- HMG-CoA:
-
3-Hydroxy-3-methyl-glutaryl-coenzyme A
- MiDAC:
-
Mitotic deacetylase complex
- NcoR:
-
Nuclear receptor corepressor
- NODE:
-
Nanog and Oct4-associated deacetylase
- NuRD:
-
Nucleosome remodeling deacetylase
- PI3K:
-
Phosphatidylinositol 3-kinase
- SAHA:
-
Suberoylanilide hydroxamic acid
- Sin3:
-
Septation initiation network transcriptional regulatory protein 3
- SMRT:
-
Silencing mediator of retinoid and thyroid receptors
References
Philipps DMP (1963) The presence of acetyl groups in histones. Biochem J 87:258–263
Allfrey VG, Faulkner R, Mirsky AE (1964) Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci U S A 51:786–794
Gallwitz D, Sekeris CE (1969) The acetylation of histones of rat liver nuclei in vitro by acetyl-CoA. Z Physiol Chem 350:150–154
Inoue A, Fujimoto D (1969) Enzymatic deacetylation of histone. Biochem Biophys Res Commun 36:146–150
He M, Han Z, Liu L et al (2018) Chemical biology approaches for investigating the functions of lysine acetyltransferases. Angew Chem Int Ed 57:1162–1184
Harmel R, Fiedler D (2018) Features and regulation of non-enzymatic posttranslational modifications. Nat Chem Biol 14:244–252
Pérez-Salvia M, Esteller M (2017) Bromodomain inhibitors and cancer therapy: from structures to applications. Epigenetics 12:323–339
Lyon K, Stasevich TJ (2017) Imaging translational and post-translational gene regulatory dynamics in living cells with antibody-based probes. Trends Genet 33:322–335
Drazic A, Myklebust LM, Ree R et al (2016) The world of protein acetylation. Biochim Biophys Acta 1864:1372–1401
Jiang H, Zhang X, Chen X et al (2018) Protein lipidation: occurrence, mechanisms, biological functions, and enabling technologies. Chem Rev 118:919–988
Reid MA, Dai Z, Locasale JW (2017) The impact of cellular metabolism on chromatin dynamics and epigenetics. Nat Cell Biol 19:1298–1306
Yoshida M, Kudo N, Kosono S et al (2017) Chemical and structural biology of protein lysine deacetylases. Proc Jpn Acad Ser B 93:297–321
Seto E, Yoshida M (2014) Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol 6:a018713
Bertrand P (2010) Inside HDAC with HDAC inhibitors. Eur J Med Chem 45:2095–2116
Micelli C, Rastelli G (2015) Histone deacetylases: structural determinants of inhibitor selectivity. Drug Discov Today 20:718–735
Roche J, Bertrand P (2016) Inside HDACs with more selective HDAC inhibitors. Eur J Med Chem 121:451–483
Kutil Z, Novakova Z, Meleshin M et al (2018) Histone deacetylase 11 is a fatty-acid deacylase. ACS Chem Biol 13:685–693
Di Giorgio E, Brancolini C (2016) Regulation of class IIa HDAC activities: it is not only matter of subcellular localization. Epigenomics 8:251–269
Desravines DC, Serna Martin I, Schneider R et al (2017) Structural characterization of the SMRT corepressor interacting with histone deacetylase. Sci Rep 7:3678
Hai Y, Christianson DW (2016) Histone deacetylase 6 structure and molecular basis of catalysis and inhibition. Nat Chem Biol 12:741–747
Yanginlar C, Logie C (2018) HDAC11 is a regulator of diverse immune functions. Biochem Biophys Acta 1861:54–59
Zwergel C, Stazi G, Valente S et al (2016) Histone deacetylase inhibitors: updated studies in various epigenetic-related diseases. J Clin Epigenetics 2:1–7
Manal M, Chandrasekar MJN, Priya JG et al (2016) Inhibitors of histone deacetylase as antitumor agents: a critical review. Bioorg Chem 67:18–42
Ganesan A (2018) Epigenetic drug discovery: a success story for cofactor interference. Philos Trans R Soc B 373:20170069
Khan A, Singh P, Srivastava K (2018) Synthesis, nature and utility of universal iron chelator – siderophore: a review. Microbiol Res 212:103–111
Codd R (2008) Traversing the coordination chemistry and chemical biology of hydroxamic acids. Coord Chem Rev 252:1387–1408
Yoshida M, Kijima M, Akita M et al (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265:17174–17179
Richon VM, Emiliani S, Verdin E et al (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A 95:3003–3007
Marks PA, Breslow R (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25:84–90
Kawai K, Nagata N (2012) Metal–ligand interactions: an analysis of zinc binding groups using the Protein Data Bank. Eur J Med Chem 51:271–276
Shen S, Kozikowski AP (2016) Why hydroxamates may not be the best histone deacetylase inhibitors – what some may have forgotten or would rather forget? ChemMedChem 11:15–21
Finn PW, Loza E, Carstensten E (2016) The discovery and development of belinostat. In: Fischer J, Childers WE (eds) Successful drug discovery, vol 2. Wiley-VCH, Weinheim, pp 31–57
Atadja P, Perez L (2016) Discovery and development of Farydak (NVP-LBH589, panobinostat) as an anticancer drug. In: Fischer J, Childers WE (eds) Successful drug discovery, vol 2. Wiley-VCH, Weinheim, pp 59–88
Maolanon AR, Madsen AS, Olsen CA (2016) Innovative strategies for selective inhibition of histone deacetylases. Cell Chem Biol 23:759–768
Novotny-Diermayr V, Sangthongpitag K, Hu CY et al (2010) SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther 9:642–652
Mandl-Weber S, Meinel FG, Jankowsky R et al (2010) The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. Br J Haematol 149:518–528
Leoni F, Fossati G, Lewis EC et al (2005) The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 11:1–15
Buggy JJ, Cao ZA, Bass KE et al (2006) CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther 5:1309–1317
Lu Q, Wang DS, Chen CS et al (2005) Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem 48:5530–5535
Arts J, King P, Mariën A et al (2009) JNJ-26481585, a novel “second-generation” oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res 15:6841–6851
Moffat D, Patel S, Day F et al (2010) Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor. J Med Chem 53:8663–8678
Santo L, Hideshima T, Kung AL et al (2012) Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 119:2579–2589
Huang P, Almeciga-Pinto I, Jarpe M et al (2017) Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models. Oncotarget 8:2694–2707
Lecointre B, Narozny R, Borrello MT et al (2018) Isoform-selective HDAC1/6/8 inhibitors with an imidazo-ketopiperazine cap containing stereochemical diversity. Philos Trans R Soc B 373:20170364
Gaisina IN, Tueckmantel W, Ugolkov A et al (2016) Identification of HDAC6-selective inhibitors of low cancer cell cytotoxicity. ChemMedChem 11:81–92
Sellmer A, Stangl H, Beyer M et al (2018) Marbostat-100 defines a new class of potent and selective antiinflammatory and antirheumatic histone deacetylase 6 inhibitors. J Med Chem 61:3454–3477
Balasubramanian S, Ramos J, Luo W et al (2008) A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 22:1026–1034
Ingham OJ, Paranal RM, Smith WB et al (2016) Development of a potent and selective HDAC8 inhibitor. ACS Med Chem Lett 7:929–932
Luckhurst CA, Breccia P, Stott AJ et al (2015) Potent, selective, and CNS-penetrant tetrasubstituted cyclopropane class IIa histone deacetylase (HDAC) inhibitors. ACS Med Chem Lett 7:34–39
Ossenkoppele GJ, Lowenberg B, Zachee P et al (2013) A phase I first-in-human study with tefinostat – a monocyte/macrophage targeted histone deacetylase inhibitor – in patients with advanced haematological malignancies. Br J Haematol 162:191–201
Zheng S, Guo S, Zhong Q et al (2018) Biocompatible boron-containing prodrugs of belinostat for the potential treatment of solid tumors. ACS Med Chem Lett 9:149–154
Ganesan A (2016) Multitarget drugs: an epigenetic epiphany. ChemMedChem 11:1227–1241
de Lera AR, Ganesan A (2016) Epigenetic polypharmacology: from combination therapy to multitargeted drugs. Clin Epigenetics 8:105
Cai X, Zhai HX, Wang J et al (2010) Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J Med Chem 53:2000–2009
Qian C, Lai CJ, Bao R et al (2012) Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. Clin Cancer Res 18:4104–4113
Shigematsu N, Ueda H, Takase S et al (1994) FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. II. Structure determination. J Antibiot 47:311–314
Nakajima H, Kim YB, Terano H et al (1998) FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 241:126–133
Furumai R, Matsuyama A, Kobashi N et al (2002) FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62:4916–4921
Taori K, Paul VJ, Luesch H (2008) Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp. J Am Chem Soc 130:1806–1807
Wang C, Henkes LM, Doughty LB et al (2011) Thailandepsins: bacterial products with potent histone deacetylase inhibitory activities and broad-spectrum antiproliferative activities. J Nat Prod 74:2031–2038
Ganesan A (2015) Macrocyclic inhibitors of zinc-dependent histone deacetylases (HDACs). In: Levin J (ed) Macrocycles in drug discovery. RSC, Cambridge, pp 109–140
Maolanon AR, Kristensen HM, Leman LJ et al (2017) Natural and synthetic macrocyclic inhibitors of the histone deacetylase enzymes. Chembiochem 18:5–49
Ganesan A (2016) Romidepsin and the zinc-binding thiol family of natural product HDAC inhibitors. In: Fischer J, Childers WE (eds) Successful drug discovery, vol 2. Wiley-VCH, Weinheim, pp 13–30
Stolze SC, Kaiser M (2013) Case studies of the synthesis of bioactive cyclodepsipeptide natural products. Molecules 18:1337–1367
Chen QY, Chaturvedi PR, Luesch H (2018) Process development and scale-up total synthesis of largazole, a potent class I histone deacetylase inhibitor. Org Process Res Dev 22:190–199
Poli G, di Fabio R, Ferrante L et al (2017) Largazole analogues as histone deacetylase inhibitors and anticancer agents: an overview of structure–activity relationships. ChemMedChem 12:1917–1926
Benelkebir H, Marie S, Hayden A et al (2011) Total synthesis of largazole and analogues: HDAC inhibition, antiproliferative activity and metabolic stability. Bioorg Med Chem 19:3650–3658
Yao Y, Tu Z, Liao C et al (2015) Discovery of novel class I histone deacetylase inhibitors with promising in vitro and in vivo antitumor activities. J Med Chem 58:7672–7680
Almaliti J, Al-Hamashi AA, Negmeldin AT et al (2016) Largazole analogues embodying radical changes in the depsipeptide ring: development of a more selective and highly potent analogue. J Med Chem 59:10642–10660
Kitir B, Maolanon AR, Ohm RG et al (2017) Chemical editing of macrocyclic natural products and kinetic profiling reveal slow, tight-binding histone deacetylase inhibitors with picomolar affinities. Biochemistry 56:5134–5146
Gu W, Nusinzon I, Smith RD Jr et al (2006) Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: potent inhibition of histone deacetylases. Bioorg Med Chem 14:3320–3329
Saito A, Yamashita T, Mariko Y et al (1999) A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A 96:4592–4597
Fournel M, Bonfils C, Hou Y et al (2008) MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 7:759–768
Lu XP, Ning ZQ, Li ZB et al (2016) Discovery and development of HDAC subtype selective inhibitor chidamide: potential immunomodulatory activity against cancers. In: Fischer J, Childers WE (eds) Successful drug discovery, vol 2. Wiley-VCH, Weinheim, pp 89–114
Ning ZQ, Li ZB, Newman MJ et al (2012) Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol 69:901–909
Witter DJ, Harrington P, Wilson KJ et al (2008) Optimization of biaryl selective HDAC1&2 inhibitors (SHI-1:2). Bioorg Med Chem Lett 18:726–731
McClure JJ, Inks ES, Zhang C et al (2017) Comparison of the deacylase and deacetylase activity of zinc-dependent HDACs. ACS Chem Biol 12:1644–1655
Candido EP, Reeves R, Davie JR (1978) Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 14:105–113
Kim SW, Hooker JM, Otto N et al (2013) Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by PET. Nucl Med Biol 40:912–918
Wen S, Carey KL, Nakao Y et al (2007) Total synthesis of azumamide A and azumamide E, evaluation as histone deacetylase inhibitors, and design of a more potent analogue. Org Lett 9:1105–1108
Porter NJ, Christianson DW (2017) Binding of the microbial cyclic tetrapeptide trapoxin A to the class I histone deacetylase HDAC8. ACS Chem Biol 12:2281–2286
Olsen CA, Montero A, Leman LJ et al (2012) Macrocyclic peptoid−peptide hybrids as inhibitors of class I histone deacetylases. ACS Med Chem Lett 3:749–753
Islam MN, Islam MS, Hoque MA et al (2014) Bicyclic tetrapeptides as potent HDAC inhibitors: effect of aliphatic loop position and hydrophobicity on inhibitory activity. Bioorg Med Chem 22:3862–3870
Traoré MDM, Zwick V, Simões-Pires CA et al (2017) Hydroxyl ketone-based histone deacetylase inhibitors to gain insight into class I HDAC selectivity versus that of HDAC6. ACS Omega 2:1550–1562
Whitehead L, Dobler MR, Radetich B et al (2011) Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors. Bioorg Med Chem 19:4626–4634
Lobera M, Madauss KP, Pohlhaus DT et al (2013) Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol 9:319–325
Attenni B, Ontoria JM, Cruz JC et al (2009) Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model. Bioorg Med Chem Lett 19:3081–3084
Li X, Peterson YK, Inks ES et al (2018) Class I HDAC inhibitors display different antitumor mechanism in leukemia and prostatic cancer cells depending on their p53 status. J Med Chem 61:2589–2603
Ononye SN, VanHeyst MD, Oblak EZ et al (2013) Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors. ACS Med Chem Lett 4:757–761
Kleinschek A, Meyners C, Digiorgio E et al (2016) Potent and selective non-hydroxamate histone deacetylase 8 inhibitors. ChemMedChem 11:2598–2606
Ontoria JM, Altamura S, Di Marco A et al (2009) Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy. J Med Chem 52:6782–6789
Boskovic ZV, Kemp MM, Freedy AM et al (2016) Inhibition of zinc-dependent histone deacetylases with a chemically triggered electrophile. ACS Chem Biol 11:1844–1851
Millard CJ, Watson PJ, Fairall L et al (2017) Targeting class I histone deacetylases in a “complex” environment. Trends Pharmacol Sci 38:363–377
Villagra A, Sahakian E, Seto E (2016) Preparation and biochemical analysis of classical histone deacetylases. Methods Enzymol 573:161–181
Newbold A, Falkenberg KJ, Prince HM et al (2016) How do tumor cells respond to HDAC inhibition? FEBS J 283:4032–4046
Bolden JE, Shi W, Jankowski K et al (2013) HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis 4:e519
Tiffon C, Adams J, van der Fits L et al (2011) The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. Br J Pharmacol 162:1590–1602
Das Gupta K, Shakespear MR, Iyer A et al (2016) Histone deacetylases in monocyte/macrophage development, activation and metabolism: refining HDAC targets for inflammatory and infectious diseases. Clin Trans Immunol 5:e62
Zhang Q, Dai Y, Cai Z et al (2018) HDAC inhibitors: novel immunosuppressants for Allo- and Xeno- transplantation. Chem Select 3:176–187
Thorlund K, Horwitz MS, Fife BT et al (2017) Landscape review of current HIV ‘kick and kill’ cure research – some kicking, not enough killing. BMC Infect Dis 17:595
Ghosh SK, Perrine SP, Williams RM et al (2012) Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood 119:1008–1017
Warnault V, Darcq E, Levine A et al (2013) Chromatin remodeling – a novel strategy to control excessive alcohol drinking. Transl Psychiatry 3:e231
Qin L, Ma K, Wang ZJ et al (2018) Social deficits in Shank3-deficient mouse models of autism are rescued by histone deacetylase (HDAC) inhibition. Nat Neurosci 21:564–575
Ooi JY, Tuano NK, Rafehi H et al (2015) HDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes. Epigenetics 10:418–430
Akimova T, Beier UH, Liu Y et al (2012) Histone/protein deacetylases and T-cell immune responses. Blood 119:2443–2451
Tsuji G, Okiyama N, Villarroel VA et al (2015) Histone deacetylase 6 inhibition impairs effector CD8 T-cell functions during skin inflammation. J Allergy Clin Immunol 135:1228–1239
Bowers ME, Xia B, Carreiro S et al (2015) The class I HDAC inhibitor RGFP963 enhances consolidation of cued fear extinction. Learn Mem 22:225–231
Bodas M, Mazur S, Min T et al (2018) Inhibition of histone-deacetylase activity rescues inflammatory cystic fibrosis lung disease by modulating innate and adaptive immune responses. Respir Res 19:2
Dirice E, Ng RWS, Martinez R et al (2017) Isoform-selective inhibitor of histone deacetylase 3 (HDAC3) limits pancreatic islet infiltration and protects female nonobese diabetic mice from diabetes. J Biol Chem 292:17598–17608
Jia H, Wang Y, Morris CD et al (2016) The effects of pharmacological inhibition of histone deacetylase 3 (HDAC3) in Huntington’s disease mice. PLoS One 11:e0152498
Usui T, Okada M, Mizuno W et al (2012) HDAC4 mediates development of hypertension via vascular inflammation in spontaneous hypertensive rats. Am J Physiol Heart Circ Physiol 302:H1894–H1904
Choi SY, Ryu Y, Kee HJ et al (2015) Tubastatin A suppresses renal fibrosis via regulation of epigenetic histone modification and Smad3-dependent fibrotic genes. Vascul Pharmacol 72:130–140
Ferrari A, Fiorino E, Longo R et al (2017) Attenuation of diet-induced obesity and induction of white fat browning with a chemical inhibitor of histone deacetylases. Int J Obes (Lond) 41:289–298
Choong CJ, Sasaki T, Hayakawa H et al (2016) A novel histone deacetylase 1 and 2 isoform-specific inhibitor alleviates experimental Parkinson’s disease. Neurobiol Aging 37:103–116
Conforti F, Davies ER, Calderwood CJ et al (2017) The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis. Oncotarget 8:48737–48754
Trifunović D, Arango-Gonzalez B, Comitato A et al (2016) HDAC inhibition in the cpfl1 mouse protects degenerating cone photoreceptors in vivo. Hum Mol Genet 25:4462–4472
Li Y, Zhao T, Liu B et al (2015) Inhibition of histone deacetylase 6 improves long-term survival in a lethal septic model. J Trauma Acute Care Surg 78:378–385
Pfaller MA, Messer SA, Georgopapadakou N et al (2009) Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens. J Clin Microbiol 47:3797–3804
Kuchler K, Jenull S, Shivarathri R et al (2016) Fungal KATs/KDACs: a new highway to better antifungal drugs? PLoS Pathog 12:e1005938
Hailu GS, Robaa D, Forgione M et al (2017) Lysine deacetylase inhibitors in parasites: past, present, and future perspectives. J Med Chem 60:4780–4804
Sumanadasa SD, Goodman CD, Lucke AJ et al (2012) Antimalarial activity of the anticancer histone deacetylase inhibitor SB939. Antimicrob Agents Chemother 56:3849–3856
Chua MJ, Arnold MS, Xu W et al (2017) Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth. Int J Parasitol Drugs Drug Resist 7:42–50
Ontoria JM, Paonessa G, Ponzi S et al (2016) Discovery of a selective series of inhibitors of Plasmodium falciparum HDACs. ACS Med Chem Lett 7:454–459
Heimburg T, Chakrabarti A, Lancelot J et al (2016) Structure-based design and synthesis of novel inhibitors targeting HDAC8 from Schistosoma mansoni for the treatment of schistosomiasis. J Med Chem 59:2423–2435
Meyners C, Wolff B, Kleinschek A et al (2017) Perfluorinated hydroxamic acids are potent and selective inhibitors of HDAC-like enzymes from Pseudomonas aeruginosa. Bioorg Med Chem Lett 27:1508–1512
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Ethics declarations
Conflict of Interest: Author declares that he has no conflict of interest.
Ethical approval: Not applicable.
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Ganesan, A. (2019). Targeting the Zinc-Dependent Histone Deacetylases (HDACs) for Drug Discovery. In: Mai, A. (eds) Chemical Epigenetics. Topics in Medicinal Chemistry, vol 33. Springer, Cham. https://doi.org/10.1007/7355_2019_68
Download citation
DOI: https://doi.org/10.1007/7355_2019_68
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-42981-2
Online ISBN: 978-3-030-42982-9
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)